We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01039194
Recruitment Status : Completed
First Posted : December 24, 2009
Last Update Posted : January 25, 2011
Information provided by:
Bristol-Myers Squibb

Brief Summary:
The purpose of the study is to find out if the plasma concentration of galantamine extended release is changed when BMS-708163 is administered at the same time.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: galantamine Drug: BMS-708163 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Study of the Effect of Concomitant Administration of Multiple Doses of BMS-708163 on the Pharmacokinetics of Galantamine in Healthy Subjects
Study Start Date : January 2010
Actual Primary Completion Date : April 2010
Actual Study Completion Date : April 2010

Arm Intervention/treatment
Active Comparator: galantamine 8 mg (ER) Drug: galantamine
Capsule, Oral, 8 mg (ER), once daily, Days 1-7
Other Name: Razadyne ER ™

Active Comparator: galantamine 16 mg (ER) Drug: galantamine
Capsule, Oral, 16 mg (ER), once daily, Days 8-24
Other Name: Razadyne ER ™

Active Comparator: BMS-708163 Drug: BMS-708163
Capsule, Oral, 125 mg, once daily, Days 15-24

Primary Outcome Measures :
  1. Galantamine alone and with BMS-708163: Galantamine PK parameters (Cmax, Tmax, AUC(TAU) and Ctrough rations will be assessed without BMS-708163 Day 14) and with BMS708-163 (Ctrough Day 24) [ Time Frame: Study Days 14 & 24 ]

Secondary Outcome Measures :
  1. Galantamine alone and with BMS 708163: Safety and tolerability (AE's, ECG, vital signs, safety labs) [ Time Frame: Study Days 7, 14, 18, 25 and study discharge ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy men and postmenopausal women

Exclusion Criteria:

  • Gastrointestinal disorders
  • Bleeding disorders
  • Peptic ulcer disease
  • Cholecystectomy
  • Seizure disorder
  • Asthma
  • Chronic obstructive pulmonary disease
  • Urinary tract obstruction
  • Cardiac conduction abnormalities, including but not limited to "sick sinus syndrome" and those with unexplained syncopal episodes
  • Inability to tolerate oral medication
  • Inability to be venipunctured and/or tolerate venous access

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01039194

Layout table for location information
United States, Maryland
Parexel International - Baltimore Epcu
Baltimore, Maryland, United States, 21225
Sponsors and Collaborators
Bristol-Myers Squibb
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Layout table for additonal information
Responsible Party: Study Director, Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01039194    
Other Study ID Numbers: CN156-009
First Posted: December 24, 2009    Key Record Dates
Last Update Posted: January 25, 2011
Last Verified: February 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Nootropic Agents